List of Rezzayo drug patents

Rezzayo is owned by Cidara Theraps.

Rezzayo contains Rezafungin Acetate.

Rezzayo has a total of 4 drug patents out of which 0 drug patents have expired.

Rezzayo was authorised for market use on 22 March, 2023.

Rezzayo is available in powder;intravenous dosage forms.

Rezzayo can be used as treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration.

Drug patent challenges can be filed against Rezzayo from 2032-03-22.

The generics of Rezzayo are possible to be released after 14 July, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8722619 CIDARA THERAPS Antifungal agents and uses thereof
Mar, 2032

(8 years from now)

US10702573 CIDARA THERAPS Dosing regimens for echinocandin class compounds
Mar, 2033

(9 years from now)

US9526835 CIDARA THERAPS Dosing regimens for echinocandin class compounds
Mar, 2033

(9 years from now)

US11197909 CIDARA THERAPS Compositions and methods for the treatment of fungal infections
Jul, 2038

(15 years from now)

Do you want to check out REZZAYO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 22, 2030
New Chemical Entity Exclusivity (NCE) Mar 22, 2028
Generating Antibiotic Incentives Now (GAIN) Mar 22, 2033

Drugs and Companies using REZAFUNGIN ACETATE ingredient

NCE-1 date: 2032-03-22

Market Authorisation Date: 22 March, 2023

Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in